Blood Donation Eligibility in Hyperthyroidism
Persons with controlled hyperthyroidism on stable antithyroid medication can donate blood, but those with active, uncontrolled thyrotoxicosis should defer donation until euthyroid.
Physiologic Rationale for Deferral in Active Disease
Hyperthyroidism produces multiple hematologic abnormalities that compromise blood donation safety:
Mild anemia is common in untreated hyperthyroidism, with hemoglobin falling below 12.0 g/dL in approximately 18% of women and below 13.0 g/dL in 28% of men, even without iron deficiency 1.
Leukopenia and neutropenia occur frequently, driven by cell cycle arrest in bone marrow hematopoietic stem/progenitor cells rather than increased apoptosis; these changes are more pronounced in female patients 2.
Pancytopenia can develop in severe cases, affecting all three cell lines through mechanisms including reduced cell lifespan and autoimmune destruction 3.
Hypercoagulability accompanies hyperthyroidism, with elevated fibrinogen, factor VIII, and von Willebrand factor increasing venous thromboembolism risk 4. This prothrombotic state creates theoretical concern that phlebotomy-induced hemoconcentration could further elevate clotting risk.
Cardiovascular Contraindications
Hyperthyroidism produces marked hemodynamic stress: cardiac output can rise to 300% of baseline, systemic vascular resistance drops, and blood volume increases by approximately 25% 5.
Patients over 50 years face cardiovascular complications as the primary cause of mortality after hyperthyroidism treatment 5. Phlebotomy-induced volume depletion in this population could precipitate tachycardia, atrial fibrillation, or heart failure.
Beta-blockers are recommended for all symptomatic hyperthyroid patients, those ≥60 years, and anyone with resting heart rate >90 bpm or cardiovascular disease 6. Blood donation in inadequately rate-controlled patients risks acute hemodynamic decompensation.
Eligibility Criteria for Controlled Disease
Patients may donate when all of the following are met:
Thyroid function is normalized (free T4 and total T3 within reference range, TSH may remain suppressed for 1–3 months after normalization) 6.
Hemoglobin meets standard donation thresholds (≥125 g/L for women, ≥130 g/L for men in most jurisdictions). Note that even "normal" hemoglobin in hyperthyroidism may represent a relative decrease, as treatment typically raises hemoglobin by 0.5 g/dL 1.
White blood cell and platelet counts are normal, confirming resolution of bone marrow suppression 2, 3.
Cardiovascular symptoms are absent and resting heart rate is controlled (<90 bpm) 6, 5.
The patient is on a stable antithyroid drug regimen (methimazole 5–15 mg daily or equivalent) without recent dose changes 6.
Specific Medication Considerations
Methimazole and carbimazole do not contraindicate donation once euthyroidism is achieved and hematologic parameters normalize 6.
Propylthiouracil carries higher hepatotoxicity risk and should be reserved for first-trimester pregnancy or thyroid storm 6. Patients on PTU require normal liver function tests before donation eligibility.
Beta-blockers (used for symptom control) do not preclude donation if heart rate and blood pressure are stable 6, 5.
Post-Radioactive Iodine or Post-Thyroidectomy Patients
After radioactive iodine therapy, patients should wait until thyroid function stabilizes (typically 3–6 months) and any transient hematologic changes resolve 6.
After thyroidectomy, patients on levothyroxine replacement with normal TSH and free T4 can donate once surgical recovery is complete and hemoglobin is adequate 6.
Common Pitfalls to Avoid
Do not assume normal hemoglobin excludes hyperthyroid-related anemia; mean corpuscular volume decreases by an average of 6 fL in hyperthyroidism even when hemoglobin is within normal range 1.
Do not permit donation in subclinical hyperthyroidism with TSH <0.1 mU/L, as these patients face increased atrial fibrillation and cardiovascular risk 7.
Do not overlook the 1.9% prevalence of pernicious anemia in hyperthyroid patients; check for macrocytosis and consider B12 levels if MCV is elevated 1.
Do not allow donation during the first 12–18 months of antithyroid drug therapy if the goal is remission, as frequent dose adjustments and monitoring are required 6.